Gabelli & Company Highlights 6 Potential Gilead Sciences (GILD) Takeover Targets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- Oil gains 3% as US-Iran peace talks in stalemate
- October Fed meeting hinges on this key economic data, Citi says
- Trump says men arrested at UK air base used by US were looking to do 'big damage'
- Oppenheimer sees AI software winners as focus shifts to ROI
- Nvidia releases AI safety software it says could have stopped Hugging Face hack
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Dollar near two-month high as US-Iran stalemate bolsters oil, Fed rate hike bets
Gilead Sciences Announces Promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations
November 16, 2016 5:00 PM ESTFOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced the promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations, with responsibility for commercial operations in North America, Europe and Japan. Mr. Meyers will become an officer of the company and member of Gileads senior leadership team.
Mr. Meyers joined Gilead in 1996 as a regional sales director and has been the Senior Vice President of North American Commercial Operations since 2007. In his 20 years at Gilead, Mr. Meyers has been instrumental in building out the companys commercial... More
Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Momelotinib for Patients With Myelofibrosis
November 16, 2016 4:15 PM ESTFOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced top-line results from two Phase 3 clinical trials (SIMPLIFY 1 and 2) evaluating momelotinib, an investigational inhibitor of Janus kinase (JAK) compared to ruxolitinib or best alternative therapy (BAT) in patients with myelofibrosis. The SIMPLIFY-1 study achieved its pre-specified primary endpoint of non-inferiority to ruxolitinib for splenic response rate at Week 24 (SRR24), defined as the percentage of patients experiencing a 35 percent reduction in spleen volume (momelotinib: 26.5%; ruxolitinib: 29.0%; 95 percent CI: -11.2% to +5.6%; p=0.011).
Non-inferiority was not achieved for the key secondary endpoint of... More
